Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease

Kazuki Kawakami, Ai Takeshita, Kenryo Furushima, Masayasu Miyajima, Ikuji Hatamura, Makoto Kuro-O, Yasuhide Furuta, Kazushige Sakaguchi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Secondary hyperparathyroidism, in which parathyroid hormone (PTH) is excessively secreted in response to factors such as hyperphosphataemia, hypocalcaemia, and low 1,25-dihydroxyvitamin D (1,25(OH) 2 D) levels, is commonly observed in patients with chronic kidney disease (CKD), and is accompanied by high levels of fibroblast growth factor 23 (FGF23). However, the effect of FGF23 on the parathyroid glands (PG) remains controversial. To bind to FGF receptors, FGF23 requires αKlotho, which is highly expressed in the PG. Here, we examined the effects of Fgfr1-3, αKlotho, or Fgfr1-4 ablation specifically in the PG (conditional knockout, cKO). When mice with early to mid-stage CKD with and without cKO were compared, plasma concentrations of calcium, phosphate, FGF23, and 1,25(OH) 2 D did not change significantly. In contrast, plasma PTH levels, which were elevated in CKD mice, were significantly decreased in cKO mice. PG from CKD mice showed augmentation of cell proliferation, which was significantly suppressed by cKO. Parathyroid tissue cultured for 4 days showed upregulation of PTH secretion and cell proliferation in response to FGF23. Both these effects were inhibited by cKO. These findings suggest that FGF23 is a long-Term inducer of parathyroid cell proliferation and PTH secretion, and is one cause of secondary hyperparathyroidism in CKD.

Original languageEnglish (US)
Article number40534
JournalScientific Reports
Volume7
DOIs
StatePublished - Jan 17 2017

Fingerprint

Secondary Hyperparathyroidism
Parathyroid Glands
Chronic Renal Insufficiency
Parathyroid Hormone
Cell Proliferation
Fibroblast Growth Factor 1
Fibroblast Growth Factor Receptors
Hypocalcemia
Helper-Inducer T-Lymphocytes
Knockout Mice
fibroblast growth factor 23
Up-Regulation

ASJC Scopus subject areas

  • General

Cite this

Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease. / Kawakami, Kazuki; Takeshita, Ai; Furushima, Kenryo; Miyajima, Masayasu; Hatamura, Ikuji; Kuro-O, Makoto; Furuta, Yasuhide; Sakaguchi, Kazushige.

In: Scientific Reports, Vol. 7, 40534, 17.01.2017.

Research output: Contribution to journalArticle

Kawakami, Kazuki ; Takeshita, Ai ; Furushima, Kenryo ; Miyajima, Masayasu ; Hatamura, Ikuji ; Kuro-O, Makoto ; Furuta, Yasuhide ; Sakaguchi, Kazushige. / Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease. In: Scientific Reports. 2017 ; Vol. 7.
@article{1e39a5a8930449838519ae264893beeb,
title = "Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease",
abstract = "Secondary hyperparathyroidism, in which parathyroid hormone (PTH) is excessively secreted in response to factors such as hyperphosphataemia, hypocalcaemia, and low 1,25-dihydroxyvitamin D (1,25(OH) 2 D) levels, is commonly observed in patients with chronic kidney disease (CKD), and is accompanied by high levels of fibroblast growth factor 23 (FGF23). However, the effect of FGF23 on the parathyroid glands (PG) remains controversial. To bind to FGF receptors, FGF23 requires αKlotho, which is highly expressed in the PG. Here, we examined the effects of Fgfr1-3, αKlotho, or Fgfr1-4 ablation specifically in the PG (conditional knockout, cKO). When mice with early to mid-stage CKD with and without cKO were compared, plasma concentrations of calcium, phosphate, FGF23, and 1,25(OH) 2 D did not change significantly. In contrast, plasma PTH levels, which were elevated in CKD mice, were significantly decreased in cKO mice. PG from CKD mice showed augmentation of cell proliferation, which was significantly suppressed by cKO. Parathyroid tissue cultured for 4 days showed upregulation of PTH secretion and cell proliferation in response to FGF23. Both these effects were inhibited by cKO. These findings suggest that FGF23 is a long-Term inducer of parathyroid cell proliferation and PTH secretion, and is one cause of secondary hyperparathyroidism in CKD.",
author = "Kazuki Kawakami and Ai Takeshita and Kenryo Furushima and Masayasu Miyajima and Ikuji Hatamura and Makoto Kuro-O and Yasuhide Furuta and Kazushige Sakaguchi",
year = "2017",
month = "1",
day = "17",
doi = "10.1038/srep40534",
language = "English (US)",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease

AU - Kawakami, Kazuki

AU - Takeshita, Ai

AU - Furushima, Kenryo

AU - Miyajima, Masayasu

AU - Hatamura, Ikuji

AU - Kuro-O, Makoto

AU - Furuta, Yasuhide

AU - Sakaguchi, Kazushige

PY - 2017/1/17

Y1 - 2017/1/17

N2 - Secondary hyperparathyroidism, in which parathyroid hormone (PTH) is excessively secreted in response to factors such as hyperphosphataemia, hypocalcaemia, and low 1,25-dihydroxyvitamin D (1,25(OH) 2 D) levels, is commonly observed in patients with chronic kidney disease (CKD), and is accompanied by high levels of fibroblast growth factor 23 (FGF23). However, the effect of FGF23 on the parathyroid glands (PG) remains controversial. To bind to FGF receptors, FGF23 requires αKlotho, which is highly expressed in the PG. Here, we examined the effects of Fgfr1-3, αKlotho, or Fgfr1-4 ablation specifically in the PG (conditional knockout, cKO). When mice with early to mid-stage CKD with and without cKO were compared, plasma concentrations of calcium, phosphate, FGF23, and 1,25(OH) 2 D did not change significantly. In contrast, plasma PTH levels, which were elevated in CKD mice, were significantly decreased in cKO mice. PG from CKD mice showed augmentation of cell proliferation, which was significantly suppressed by cKO. Parathyroid tissue cultured for 4 days showed upregulation of PTH secretion and cell proliferation in response to FGF23. Both these effects were inhibited by cKO. These findings suggest that FGF23 is a long-Term inducer of parathyroid cell proliferation and PTH secretion, and is one cause of secondary hyperparathyroidism in CKD.

AB - Secondary hyperparathyroidism, in which parathyroid hormone (PTH) is excessively secreted in response to factors such as hyperphosphataemia, hypocalcaemia, and low 1,25-dihydroxyvitamin D (1,25(OH) 2 D) levels, is commonly observed in patients with chronic kidney disease (CKD), and is accompanied by high levels of fibroblast growth factor 23 (FGF23). However, the effect of FGF23 on the parathyroid glands (PG) remains controversial. To bind to FGF receptors, FGF23 requires αKlotho, which is highly expressed in the PG. Here, we examined the effects of Fgfr1-3, αKlotho, or Fgfr1-4 ablation specifically in the PG (conditional knockout, cKO). When mice with early to mid-stage CKD with and without cKO were compared, plasma concentrations of calcium, phosphate, FGF23, and 1,25(OH) 2 D did not change significantly. In contrast, plasma PTH levels, which were elevated in CKD mice, were significantly decreased in cKO mice. PG from CKD mice showed augmentation of cell proliferation, which was significantly suppressed by cKO. Parathyroid tissue cultured for 4 days showed upregulation of PTH secretion and cell proliferation in response to FGF23. Both these effects were inhibited by cKO. These findings suggest that FGF23 is a long-Term inducer of parathyroid cell proliferation and PTH secretion, and is one cause of secondary hyperparathyroidism in CKD.

UR - http://www.scopus.com/inward/record.url?scp=85009889582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009889582&partnerID=8YFLogxK

U2 - 10.1038/srep40534

DO - 10.1038/srep40534

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 40534

ER -